4D Molecular Therapeutics Advances Toward Phase 3 Milestones in Retina Gene Therapy
13.02.2026 - 11:51:32
4D Molecular Therapeutics is accelerating toward key clinical benchmarks in the field of gene therapy. With multiple programs moving into late-stage development, market participants are zeroing in on long-term safety and durability of the company?s drug candidates. The central question remains whether the platform can live up to the high expectations placed upon it.
The company is prioritizing treatments for ocular vascular diseases, with the leading candidate aimed at wet age-related macular degeneration (AMD) at the forefront. Recruitment for the North American trials has progressed successfully, and the plan now targets broader global expansion of these studies.
Investors are also awaiting long-term data from existing Phase 2 programs to evaluate how effectively the vector-based delivery platform performs over multiple years. In parallel, 4D Molecular Therapeutics is expanding its clinical activity into diabetic macular edema to broaden the therapeutic reach of its pipeline.
Key 2026 Milestones
For the current year, several major events are scheduled on both clinical and financial calendars:
